Global Healthcare

Asthma and COPD Drugs Market Size, Share, Production, Growth, Trends, and Forecast 2019-2026

Press release   •   Sep 14, 2019 18:12 BST

The global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $57,359 million by 2026, registering a CAGR of 4.8% from 2019 to 2026. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted around for around half of the Global Asthma and COPD Drugs market share in 2015.

Increase in incidence and prevalence of asthma and COPD, growing geriatric population, technological advancement in the treatment of asthma and COPD diseases, growth in initiatives implemented by the government and non-government associations around the Global are the factors that majorly drive the growth of this market. However, stringent government regulations for the product approval, patent expiry of branded drugs, and side effects associated with drugs restrict the market growth.

In 2015, the asthma segment accounted for over 65% share of the overall Asthma and COPD Drugs market. Increase in introduction of generic drugs, and rising prevalence of asthma coupled with geriatric population and changes in lifestyle are the major factors that attribute to the rise in growth of this market.

Request for Free Sample Copy, Click Here@ https://www.visionresearchreports.com/report/sample/24892

Among the medication classes, the combination products segment held major share of the Global COPD and asthma drug market in 2015. This segment is expected to maintain its leading position in the overall market throughout the analysis period, primarily because of increase in focus on the effective asthma and COPD management and increase in the research and development of innovative treatment of the diseases.

North America led the market share in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the Asthma and COPD Drugs market in these regions attributes to the increase in the asthma and COPD patients, technological advancement in the treatment. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 5.1% during the analysis period. This is mainly due to the increase in adoption rate for the technological advancement for treating asthma and COPD diseases. In addition, increase in research outsourcing from emerging markets, improvement of healthcare infrastructures, and increase in expenditures in the emerging markets (such as India and China) have boosted the market growth.

The key players of the Global Asthma and COPD Drugs market are employing novel concepts and ideas to improve, manage and control asthma & COPD, and also enhance their profitability so as to gain a competitive edge over the other market players. Seretide/Advair, Symbicort, and Singular were leading brands and accounted for around one-fourth share in Global Asthma and COPD Drugs market.

The key players in the Asthma and COPD Drugs market are highly focused on expanding their business operations in the fast-growing emerging countries with new product launches as the preferred strategy. The key players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries(Israel), Vectura Group (U.K), and Pfizer Inc. (U.S).

Request to Buy this Premium Report from Here@ https://www.visionresearchreports.com/report/cart/24892

ASTHMA AND COPD DRUGS MARKET KEY SEGMENTS

By Diseases

  • COPD
  • Asthma

By Medication Class

  • Combination Products
    • Seretide/Advair
    • Symbicort
    • Relvar/Breo Ellipta
    • Flutiform
    • Dulera
    • Others
  • Leukotriene Antagonists (LTA)
    • Singulair
    • Others
  • Inhaled Corticosteroids (ICS)
    • Qvar
    • Pulmicort
    • Aerospan
    • Flovent
    • Others
  • Anticholinergics
    • Spiriva
    • Others
  • Short Acting Beta Agonists(SABA)
    • ProAir
    • Ventolin
    • Others
  • Long Acting Beta Agonists (LABA)
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa
  • Request to Buy this Premium Report from Here@ https://www.visionresearchreports.com/report/cart/24892